For instance, an earlier study in patients with treatment-resistant depression showed that the tumor necrosis factor antagonist infliximab reduced depressive symptoms to a greater extent than placebo when baseline CRP levels were above 5 mg/L compared to when CRP levels were below this threshold [31]. Here, CRP is linked to depressive symptom measurement.